We were delighted to speak with Prof. Tina Vilsbøll (University of Copenhagen, Copenhagen, Denmark) about the approval of semaglutide and the impact on the GLP-1RA landscape, and the movement towards individualizing care in patients with type 2 diabetes.
- What has been the impact of the approval of oral semaglutide in the GLP-1RA landscape? (0:15)
- How have recent advances impacted on the opportunity for individualised diabetes care? (1:19)
- What factors should be considered in tailoring oral GLP-1RA therapy to the individual? (2:29)
- How do you see the role of oral GLP-1RAs evolving in the future? (3:42)
Disclosures: Prof. Tina Vilsbøll reports financial disclosures with the following: Amgen, AZ, BMS, Boehringer, Gielad, Lilly, Novo, Sanofi, Sunpharma.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of the European Association for the Study of Diabetes (EASD) 2020.
Share this Video
Related Videos In Diabetes
Andrew Boulton, IDF 2021: Anticipated Congress Highlights
It was a pleasure to meet with IDF President, Prof. Andrew Boulton (University of Manchester, UK) ahead of this year’s virtual meeting to discuss anticipated congress highlights and the relationship between COVID-19 and diabetes. Questions What do you expect to be the highlights of this year’s IDF Congress? (0:20) What have we learned about the […]
IDF Virtual 2021 – Diabetes Complications and Covid-19
The International Diabetes Federation will organise a Virtual Congress on December 6-11, 2021. It will feature the latest research on diabetes complications and sessions dedicated to COVID-19 and diabetes, the centenary of insulin and the IDF Diabetes Atlas 10th Edition. Discover the Congress at https://idf2021.org
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!